Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1990 Jun;34(6):1007–1013. doi: 10.1128/aac.34.6.1007

Crossover assessment of serum bactericidal activity and pharmacokinetics of five broad-spectrum cephalosporins in the elderly.

R G Deeter 1, M P Weinstein 1, K A Swanson 1, J S Gross 1, L C Bailey 1
PMCID: PMC171747  PMID: 2393258

Abstract

To better define the pharmacokinetics and serum bactericidal activity (SBA) of the expanded-spectrum cephalosporins in the elderly, we administered single 2-g intravenous infusions of cefoperazone, cefotaxime, ceftriaxone, ceftazidime, and ceftizoxime to six healthy volunteers over the age of 65 years. Serum was collected over 24 h, and concentrations were determined by high-performance liquid chromatography; pharmacokinetic parameters were determined for each drug. SBA was measured against representative strains of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, and Pseudomonas aeruginosa. All agents tested had excellent SBAs against E. coli and K. pneumoniae, often for a longer duration than would be expected on the basis of conventional dosing regimens. Ceftazidime had the greatest SBA against E. aerogenes and was the only agent with a substantial SBA against P. aeruginosa. Although ceftizoxime had the greatest SBA against S. aureus, none of these cephalosporins had substantial antistaphylococcal SBAs. Pharmacokinetic analysis revealed that cefoperazone and ceftriaxone had markedly different concentration-time profiles in the elderly volunteers than would have been expected on the basis of existing data from younger volunteers. For older patients, dosing guidelines for these two agents may need to be altered.

Full text

PDF
1007

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balant L., Dayer P., Auckenthaler R. Clinical pharmacokinetics of the third generation cephalosporins. Clin Pharmacokinet. 1985 Mar-Apr;10(2):101–143. doi: 10.2165/00003088-198510020-00001. [DOI] [PubMed] [Google Scholar]
  2. Balant L., Dayer P., Rudhardt M., Allaz A. F., Fabre J. Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats. Clin Ther. 1980;3(Spec Issue):50–59. [PubMed] [Google Scholar]
  3. Barriere S. L., Ely E., Kapusnik J. E., Gambertoglio J. G. Analysis of a new method for assessing activity of combinations of antimicrobials: area under the bactericidal activity curve. J Antimicrob Chemother. 1985 Jul;16(1):49–59. doi: 10.1093/jac/16.1.49. [DOI] [PubMed] [Google Scholar]
  4. Barriere S. L., Ozasa D. C., Mordenti J. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects. Antimicrob Agents Chemother. 1985 Jul;28(1):55–57. doi: 10.1128/aac.28.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cochet B., Belaieff J., Allaz A. F., Rudhardt M., Balant L., Fabre J. Decreased extrarenal clearance of cefoperazone in hepatocellular diseases. Br J Clin Pharmacol. 1981 Apr;11(4):389–390. doi: 10.1111/j.1365-2125.1981.tb01139.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Coleman D. L., Horwitz R. I., Andriole V. T. Association between serum inhibitory and bactericidal concentrations and therapeutic outcome in bacterial endocarditis. Am J Med. 1982 Aug;73(2):260–267. doi: 10.1016/0002-9343(82)90188-7. [DOI] [PubMed] [Google Scholar]
  8. Craig W. A. Single-dose pharmacokinetics of cefoperazone following intravenous administration. Clin Ther. 1980;3(Spec Issue):46–49. [PubMed] [Google Scholar]
  9. Cutler R. E., Blair A. D., Burgess E. D., Parks D. Pharmacokinetics of ceftizoxime. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):91–97. doi: 10.1093/jac/10.suppl_c.91. [DOI] [PubMed] [Google Scholar]
  10. Drusano G. L., Joshi J., Forrest A., Ruxer R., Standiford H., Leslie J., Wade J., Schimpff S. Pharmacokinetics of ceftazidime, alone or in combination with piperacillin or tobramycin, in the sera of cancer patients. Antimicrob Agents Chemother. 1985 Apr;27(4):605–607. doi: 10.1128/aac.27.4.605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Goodpasture H. C., Gerlach E. H., Jones R. N., Peterie J. D. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titers and drug concentrations 8 and 12 hr after 1- or 2-gm infusions. Diagn Microbiol Infect Dis. 1988 Feb;9(2):97–103. doi: 10.1016/0732-8893(88)90102-2. [DOI] [PubMed] [Google Scholar]
  12. Guglielmo B. J., Rodondi L. C. Comparison of antibiotic activities by using serum bactericidal activity over time. Antimicrob Agents Chemother. 1988 Oct;32(10):1511–1514. doi: 10.1128/aac.32.10.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayton W. L., Stoeckel K. Age-associated changes in ceftriaxone pharmacokinetics. Clin Pharmacokinet. 1986 Jan-Feb;11(1):76–86. doi: 10.2165/00003088-198611010-00005. [DOI] [PubMed] [Google Scholar]
  14. Heim-Duthoy K. L., Bubrick M. P., Cocchetto D. M., Matzke G. R. Disposition of ceftazidime in surgical patients with intra-abdominal infection. Antimicrob Agents Chemother. 1988 Dec;32(12):1845–1847. doi: 10.1128/aac.32.12.1845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jonsson M., Walder M. Pharmacokinetics of intravenous antibiotics in acutely ill elderly patients. Eur J Clin Microbiol. 1986 Dec;5(6):629–633. doi: 10.1007/BF02013286. [DOI] [PubMed] [Google Scholar]
  16. Klastersky J. The bactericidal activity in serum and its prognostic clinical value. Infection. 1983;11 (Suppl 2):S93–S96. doi: 10.1007/BF01645296. [DOI] [PubMed] [Google Scholar]
  17. Lam Y. W., Duroux M. H., Gambertoglio J. G., Barriere S. L., Guglielmo B. J. Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers. Antimicrob Agents Chemother. 1988 Mar;32(3):298–302. doi: 10.1128/aac.32.3.298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. LeBel M., Barbeau G., Vallee F., Bergeron M. G. Pharmacokinetics of ceftazidime in elderly volunteers. Antimicrob Agents Chemother. 1985 Nov;28(5):713–715. doi: 10.1128/aac.28.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Leggett J. E., Craig W. A. Enhancing effect of serum ultrafiltrate on the activity of cephalosporins against gram-negative bacilli. Antimicrob Agents Chemother. 1989 Jan;33(1):35–40. doi: 10.1128/aac.33.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ljungberg B., Nilsson-Ehle I. Pharmacokinetics of ceftazidime in elderly patients and young volunteers. Scand J Infect Dis. 1984;16(3):325–326. doi: 10.3109/00365548409070410. [DOI] [PubMed] [Google Scholar]
  21. Luderer J. R., Patel I. H., Durkin J., Schneck D. W. Age and ceftriaxone kinetics. Clin Pharmacol Ther. 1984 Jan;35(1):19–25. doi: 10.1038/clpt.1984.3. [DOI] [PubMed] [Google Scholar]
  22. Lüthy R., Blaser J., Bonetti A., Simmen H., Wise R., Siegenthaler W. Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime. Antimicrob Agents Chemother. 1981 Nov;20(5):567–575. doi: 10.1128/aac.20.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McCormick E. M., Echols R. M., Rosano T. G. Liquid chromatographic assay of ceftizoxime in sera of normal and uremic patients. Antimicrob Agents Chemother. 1984 Mar;25(3):336–338. doi: 10.1128/aac.25.3.336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Meyers B. R., Mendelson M. H., Deeter R. G., Srulevitch-Chin E., Sarni M. T., Hirschman S. Z. Pharmacokinetics of cefoperazone in ambulatory elderly volunteers compared with young adults. Antimicrob Agents Chemother. 1987 Jun;31(6):925–929. doi: 10.1128/aac.31.6.925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mühlberg W., Platt D. Cefotaxim. Pharmakokinetik bei geriatrischen Patienten mit Multimorbidität. Med Welt. 1982 Apr 16;33(15):551–560. [PubMed] [Google Scholar]
  26. Naber K. G., Kees F., Grobecker H. Ceftazidime: pharmacokinetics in young volunteers versus elderly patients and therapeutic efficacy with complicated urinary tract infections. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):41–45. doi: 10.1093/jac/12.suppl_a.41. [DOI] [PubMed] [Google Scholar]
  27. Naber K., Adam D. Pharmakokinetik von Cefotaxim bei geriatrischen Patienten. MMW Munch Med Wochenschr. 1980 Nov 14;122(46):1651–1654. [PubMed] [Google Scholar]
  28. Patel I. H., Miller K., Weinfeld R., Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy. 1981;27 (Suppl 1):47–56. doi: 10.1159/000238029. [DOI] [PubMed] [Google Scholar]
  29. Quintiliani R., Nightingale C. H. Comparative pharmacokinetics of ceftizoxime and other third-generation cephalosporins in humans. J Antimicrob Chemother. 1982 Nov;10 (Suppl 100):99–104. doi: 10.1093/jac/10.suppl_c.99. [DOI] [PubMed] [Google Scholar]
  30. Reller L. B., Stratton C. W. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis. 1977 Aug;136(2):196–204. doi: 10.1093/infdis/136.2.196. [DOI] [PubMed] [Google Scholar]
  31. Schwartz J. I., Jauregui L. E., Bachmann K. A., Martin M. E., Reitberg D. P. Multiple-dose pharmacokinetics of intravenously administered cefoperazone and sulbactam when given in combination to infected, seriously ill, elderly patients. Antimicrob Agents Chemother. 1988 May;32(5):730–735. doi: 10.1128/aac.32.5.730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sculier J. P., Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. doi: 10.1016/0002-9343(84)90662-4. [DOI] [PubMed] [Google Scholar]
  33. Signs S. A., File T. M., Tan J. S. High-pressure liquid chromatographic method for analysis of cephalosporins. Antimicrob Agents Chemother. 1984 Nov;26(5):652–655. doi: 10.1128/aac.26.5.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Stratton C. W., Weinstein M. P., Reller L. B. Correlation of serum bactericidal activity with antimicrobial agent level and minimal bactericidal concentration. J Infect Dis. 1982 Feb;145(2):160–168. doi: 10.1093/infdis/145.2.160. [DOI] [PubMed] [Google Scholar]
  35. Van Laethem Y., Lagast H., Husson M., Klastersky J. Serum bactericidal activity of cefoperazone and ceftazidime at increasing dosages against Pseudomonas aeruginosa. J Antimicrob Chemother. 1983 Nov;12(5):475–480. doi: 10.1093/jac/12.5.475. [DOI] [PubMed] [Google Scholar]
  36. Van Laethem Y., Lagast H., Klastersky J. Serum bactericidal activity of ceftazidime and cefoperazone alone or in combination with amikacin against Pseudomonas aeruginosa and Klebsiella pneumoniae. Antimicrob Agents Chemother. 1983 Mar;23(3):435–439. doi: 10.1128/aac.23.3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Warns H., Lode H., Harnoss C. M., Kemmerich B., Koeppe P., Wagner J. Multiple dose pharmacokinetics and therapeutic results with ceftazidime. J Antimicrob Chemother. 1983 Jul;12 (Suppl A):235–240. doi: 10.1093/jac/12.suppl_a.235. [DOI] [PubMed] [Google Scholar]
  38. Weinstein M. P., Stratton C. W., Ackley A., Hawley H. B., Robinson P. A., Fisher B. D., Alcid D. V., Stephens D. S., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. doi: 10.1016/0002-9343(85)90436-x. [DOI] [PubMed] [Google Scholar]
  39. Weinstein M. P., Stratton C. W., Hawley H. B., Ackley A., Reller L. B. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med. 1987 Aug;83(2):218–222. doi: 10.1016/0002-9343(87)90688-7. [DOI] [PubMed] [Google Scholar]
  40. Wolfson J. S., Swartz M. N. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. doi: 10.1056/NEJM198504113121507. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES